Social Anxiety Disorder: Nursing Case Study and Treatment Plan
This paper presents a comprehensive nursing case study of a 45-year-old African American female diagnosed with social anxiety disorder (ICD-10: F40.10). The paper covers the patient's chief complaint, demographic background, risk factors, history of present illness, and objective clinical findings. It then outlines a full treatment plan, including pathophysiology, pharmacological options (SSRIs, MAOIs, benzodiazepines), diagnostic testing via the GAD-7 scale, cognitive-behavioral therapy (CBT) as the primary intervention, patient education through social skills training, and a structured five-point behavioral plan. Follow-up protocols and quality improvement considerations are also addressed.
- Patient Overview and Chief Complaint: Demographics, chief complaint, medications, and allergies
- History, Risk Factors, and Objective Findings: Risk factors, HPI, past medical history, and clinical exam
- Primary Diagnosis and Pathophysiology: DSM-5 diagnosis, neurobiology, and pharmacological background
- Pharmacological Treatment and Diagnostic Testing: FDA-approved medications, GAD-7 scale, and lab considerations
- Interventions, Education, and Follow-Up: CBT, social skills training, prevention, and follow-up schedule
- Five-Point Treatment Plan and Quality Considerations: Structured behavioral plan and quality improvement strategies
- Analysis and Conclusion: Synthesis of diagnosis, treatment rationale, and expected outcomes
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper integrates clinical detail (vital signs, objective exam findings, psychiatric observation) with evidence-based treatment reasoning, giving it the practical depth expected of a graduate-level nursing case study.
- It grounds the diagnosis in both DSM-5 criteria and ICD-10 coding, demonstrating familiarity with standardized diagnostic frameworks used in clinical practice.
- The five-point treatment plan is concrete and patient-specific, referencing the patient's actual history (racial discrimination, workplace presentations, family history of CAD) rather than offering generic recommendations.
Key academic technique demonstrated
The paper models the SOAP-adjacent clinical documentation format common in nursing education: it moves systematically from subjective complaint to objective data, then assessment (diagnosis and pathophysiology), and finally a multi-modal plan (pharmacology, therapy, education, labs, follow-up, referrals). This structure teaches students how to organize clinical reasoning in a format directly transferable to practice.
Structure breakdown
The paper opens with patient demographics and the chief complaint, then builds a detailed history (HPI, PMHX, ROS). The middle sections address diagnosis, pathophysiology, and treatment options (medications, CBT, patient education). The closing sections present a five-point behavioral plan, quality improvement notes, and a synthesis analysis that ties pharmacological and therapeutic recommendations back to the patient's specific clinical picture. References follow APA format throughout.
Patient Overview and Chief Complaint
Age: 45 years | Race: African American | Gender: Female
The patient came to the clinic reporting that she fears strangers and even acquaintances she has met at her workplace, and that she has been experiencing this for the past year — the same period during which she moved to her current location. As a member of a social minority, she has faced racial discrimination. She could not stop crying and noted that this was routine whenever she felt low, even at home. She also felt that racial discrimination may be why she has developed a fear of people and avoids mingling with them, other than her family at home and two or three close friends at the workplace.
Demographic Data: The patient is married and has three children. She has completed a Master's degree in Nursing Studies and works as a full-time nurse. She does not drink alcohol but smokes 20 packs per year (PPY).
Medications and Allergies: The patient has no known drug allergies (NKDA). She is currently taking Lisinopril (10 mg) daily.
History, Risk Factors, and Objective Findings
Several risk factors are relevant to her condition. Her temperament changes when she is exposed to people who are strangers or even acquaintances at the office. She experiences a persistent fear that she is being watched or that people are talking about her, and she fears being ridiculed — all of which cause sudden changes in her mood. Although her supervisor is aware of some of her symptoms, her symptoms are triggered merely by the thought of having to give presentations at work.
As a member of an African American family, some of her relatives had experienced stress and mild depression. Since she moved to her current area within the United States, she has encountered serious racism that has affected her deeply. It has begun to affect her work and family life, as she is afraid to go out in her neighborhood. Her sister reported that as a child — around age ten — her teacher scolded her harshly for poor performance on a test. Following that incident, she became fearful of all her teachers and participated less in class. She was frightened when school assignments required giving presentations in front of the class and was uncomfortable standing before a group of peers. She had a small circle of friends from the beginning of her school years and did not interact easily with boys.
Surgeries: None. Hospitalization: None. Family History: None specified. Vaccination: Current with vaccination schedule.
Social History: The patient owns her home with her husband and three children. Her mother passed away from coronary artery disease (CAD); her father is still alive. Her grandmother showed no notable signs of illness, but her grandfather experienced stress after age 50 due to financial difficulties.
Developmental History: Her sister reported no developmental difficulties other than some symptoms of fearfulness during her second and third pregnancies.
General Appearance: The patient appeared generally healthy but noted she had gained 20 lbs. in the past year. She recently felt motivated to lose weight, as the overnight weight gain increased her worries. She was wearing clean clothes; the first two buttons of her shirt were undone, as the second button was missing. She appeared weary and tired, and her eyes were puffy from persistent crying.
Level of Consciousness (LOC): She appeared to be in a distant state of mind at times — as if looking at something while deep in thought.
Vital Signs: Temperature: 98.6°F | HR: 65 | RR: 18 | BP: 110/68 | Height/Weight: 66" / 220 lbs.
HEENT: The patient frequently complained of headaches and postnatal depression (PND), particularly after her third pregnancy. Her eyes showed mild redness from constant crying. Ears, nose, and throat appeared normal.
PULM: Clear to all bases; anterior/posterior symmetrical.
CV: Regular rate and rhythm (RRR); S1 S2, no click, rub, or gallop.
GI/GU: Abdomen was soft, non-tender, with no masses observed. GU was deferred.
EXT: No clubbing, cyanosis, or edema; palpable DP/PT bilaterally 2+/2+.
Psychiatric Exam: Orientation/Consciousness: X4. Attention, memory, and intellect appeared intact, sufficient for meaningful conversation. The patient did not raise her voice and appeared afraid of the clinical environment, consistent with her fear of strangers and reluctance to engage in conversation. Her affect showed persistent fright; she clung to her chair, leaning backward and inward. She trembled once or twice while recounting workplace experiences, and had difficulty voicing certain words.
Thought Processes: The patient exhibited several dysfunctional thought patterns including black-and-white thinking, mental filtering, and overgeneralization (Cuncic, 2021).
Thought Content: Most of her thoughts involved self-blame; she believed there was always something wrong with her that caused her to fear people. She generalized all types of people in the same way and tended to perceive situations negatively. She distinguished situations in two extremes, with no middle ground in her thinking.
Reliability/Insight/Judgment: She was present and engaged for most of the conversation but appeared distant at times. She exhibited intense anxiety about social situations and reported worrying excessively for days before anticipated events.
Suicidal/Homicidal Ideation (SI/HI): No such indications were reported by the patient or her sister.
PULM: Reports a new, non-productive cough; denies wheezing.
CV: History of cardiac murmur and non-sustained ventricular tachycardia (NSVT); denies chest pain or recent palpitations.
GI/GU: Denies nausea, vomiting, diarrhea, constipation, blood in urine, or blood in stool.
EXT: Denies pain, tingling, or numbness in upper or lower extremities; denies edema.
Psych: Remote history of overeating, particularly binge eating during periods of stress.
Primary Diagnosis and Pathophysiology
The patient's primary diagnosis is social anxiety disorder. The DSM-5 and ICD-10 code for this disorder is F40.10 (ICD10Data.com, 2021).
Social anxiety disorder is a mental and social disorder in which the individual fears facing social situations and interacting with other people (Rose & Tadi, 2021). The affected person feels ashamed and embarrassed when confronting others. Exposure to social situations and gatherings instills fear and anxiety; the individual perceives that they will be judged negatively by those around them, and adverse social experiences begin to permeate their thinking.
People with this disorder show faster heart rates as an autonomic nervous system response, along with changes in neurological functioning when exposed to social situations (Rose & Tadi, 2021). The pathogenesis of social anxiety disorder also reveals distortions in neurotransmitter systems caused by altered levels of serotonin, dopamine, and glutamate. Brain imaging of individuals with social anxiety disorder shows greater activity in the paralimbic and limbic regions.
Several medications and interventions have been proposed. Research has suggested irreversible monoamine oxidase inhibitors (MAOIs), beta-blockers, reversible monoamine oxidase A inhibitors (RIMAs), and high-potency benzodiazepines (Williams et al., 2017). Subsequent studies reported positive outcomes from serotonin reuptake inhibitors (SSRIs) and newer agents such as GW876008 (NCT00397722), buspirone, noradrenergic and specific serotonergic antidepressants like mirtazapine, the newer-generation agent olanzapine, selected dosages of the noradrenaline reuptake inhibitor (NARI) atomoxetine, and the serotonin antagonist and reuptake inhibitor (SARI) nefazodone (Williams et al., 2017). Certain anticonvulsants and gamma-aminobutyric acid (GABA) agents have also been valued for the same purpose (Williams et al., 2017). Behavioral therapies have proven most effective, as changes in attitudes are the true drivers of positive health outcomes in anxiety patients.
References
Celestine, N. (2021, January 30). 5 quality of life questionnaires and assessments. Positive Psychology. https://positivepsychology.com/quality-of-life-questionnaires-assessments/
Cuncic, A. (2021, March 15). Social anxiety disorder thought patterns to avoid. Very Well Mind.
Felman, A. (2020, October 7). What to know about social anxiety disorder. Medical News Today. https://www.medicalnewstoday.com/articles/176891
Higuera, V. (2018, September 3). Social anxiety disorder. Healthline. https://www.healthline.com/health/anxiety/social-phobia
ICD10Data.com. (2021, October 1). 2022 ICD-10-CM diagnosis code F40.10, social phobia, unspecified. https://www.icd10data.com/ICD10CM/Codes/F01-F99/F40-F48/F40-/F40.10
National Institute for Health and Care Excellence. (2013, May 22). Guidance.
Olivares-Olivares, P. J., Ortiz-González, P. F., & Olivares, J. (2019). Role of social skills training in adolescents with social anxiety disorder. International Journal of Clinical and Health Psychology: IJCHP, 19(1), 41–48. https://doi.org/10.1016/j.ijchp.2018.11.002
Rose, G. M., & Tadi, P. (2021). Social anxiety disorder. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK555890/
Sapra, A., Bhandari, P., Sharma, S., Chanpura, T., & Lopp, L. (2020). Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a primary care setting. Cureus, 12(5), e8224. https://doi.org/10.7759/cureus.8224
Stiles-Shields, C., Ho, J., & Mohr, D. C. (2016). A review of design characteristics of cognitive-behavioral therapy-informed behavioral intervention technologies for youth with depression and anxiety. Digital Health, 2, 2055207616675706.
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017). Pharmacotherapy for social anxiety disorder (SAnD). The Cochrane Database of Systematic Reviews, 10(10), CD001206.
Always verify citation format against your institution’s current style guide requirements.